Nick Quinn-Bohmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nick Quinn-Bohmann has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Sean M. Gibbons
Institute for Systems Biology, Seattle, WA, USA
3 shared publications - Alex V. Carr
Institute for Systems Biology, Seattle, WA 98109, USA
1 shared publication - Andrew T. Magis
Institute for Systems Biology, Seattle, WA 98109, USA
1 shared publication - Charles W. Drescher
Swedish Cancer Institute, Seattle, WA
1 shared publication - Christian Diener
Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
1 shared publication Danielle Burgio
Providence Swedish Cancer Institute, Seattle, WA 98104, USA
1 shared publication
Latest Publications
- Open Access
Longitudinal multi-omic profiling separates persistent from resolving sequelae of breast cancer treatment
Long-term treatment sequelae shape health and quality of life for years after breast cancer, yet why some women develop them and others recover remains unclear. Here we follow 16 women through chemotherapy and for two years afterwards, with patient-reported symptoms, clinical chemistries, plasma proteomics, metabolomics, and gut microbiome profiles collected across eight visits from a pre-treatment baseline. Sequelae differ in their timing, with some resolving as chemotherapy ends, whereas fatigue, memory problems, and gas bloating can persist, and weight gain and joint pain can appear only afterwards. Weight gain over the second year scales with the cumulative duration of endocrine therapy and is steepest in premenopausal women. The women who remain fatigued at two years are distinguished by a second surge in fatigue scores beginning around 12 months post-chemotherapy rather than by a failure to recover, as well as by elevated plasma INHBB and depleted RAB37. INHBB is also elevated in UK Biobank participants reporting chronic, moderate, or severe fatigue, measured on the same platform. In the gut microbiome, Faecalibacterium prausnitzii, a butyrate producer, is depleted in the fatigued group at 24 months post-chemotherapy. Our analysis revealed that post-treatment sequelae follow distinct trajectories, each with its own onset. Markers that track those trajectories point to time windows in which intervention could begin before symptoms become established.
Open AccessLongitudinal multi-omic profiling separates persistent from resolving sequelae of breast cancer treatment
Long-term treatment sequelae shape health and quality of life for years after breast cancer, yet why some women develop them and others recover remains unclear. Here we follow 16 women through chemotherapy and for two years afterwards, with patient-reported symptoms, clinical chemistries, plasma proteomics, metabolomics, and gut microbiome profiles collected across eight visits from a pre-treatment baseline. Sequelae differ in their timing, with some resolving as chemotherapy ends, whereas fatigue, memory problems, and gas bloating can persist, and weight gain and joint pain can appear only afterwards. Weight gain over the second year scales with the cumulative duration of endocrine therapy and is steepest in premenopausal women. The women who remain fatigued at two years are distinguished by a second surge in fatigue scores beginning around 12 months post-chemotherapy rather than by a failure to recover, as well as by elevated plasma INHBB and depleted RAB37. INHBB is also elevated in UK Biobank participants reporting chronic, moderate, or severe fatigue, measured on the same platform. In the gut microbiome, Faecalibacterium prausnitzii, a butyrate producer, is depleted in the fatigued group at 24 months post-chemotherapy. Our analysis revealed that post-treatment sequelae follow distinct trajectories, each with its own onset. Markers that track those trajectories point to time windows in which intervention could begin before symptoms become established.
- Open Access
Metabolic modeling reveals determinants of prebiotic and probiotic treatment efficacy across two human intervention trials
Prebiotic, probiotic, and combined (synbiotic) interventions often show variable outcomes across individuals, driven by complex interactions between introduced biotics, the endogenous microbiota, and the host diet. Predicting individual-specific success or failure of probiotic and prebiotic therapies remains a major challenge. Here, we leverage microbial community-scale metabolic models (MCMMs) to forecast probiotic engraftment and microbiota-mediated short-chain fatty acid (SCFA) production in response to probiotic and prebiotic interventions. Using data from two clinical trials, testing a five-strain probiotic combined with the prebiotic inulin designed to improve metabolic health and an eight-strain probiotic designed to treat recurrent Clostridioides difficile infections, respectively, we show that MCMM-predicted engraftment largely agrees with measurements, achieving 75-80% accuracy. Engraftment probabilities varied across taxa, with Akkermansia muciniphila and Bifidobacterium infantis showing higher predicted and observed engraftment than the clostridial strains. MCMMs captured treatment-driven shifts in predicted SCFA production, and higher model-predicted growth rates of A. muciniphila were negatively associated with glucose AUC in the synbiotic trial, providing clues about the mechanisms underlying treatment efficacy. Finally, extending these models to a longitudinal cohort undergoing a healthy diet and lifestyle intervention revealed substantial inter-individual variability in predicted responses to increasing dietary fiber, which were significantly associated with baseline-to-follow-up changes in cardiometabolic health markers. Finally, our simulation results suggested that personalized prebiotic selection may further enhance probiotic efficacy. Together, these findings demonstrate the potential of metabolic modeling to guide personalized microbiome-mediated interventions.
Open AccessMetabolic modeling reveals determinants of prebiotic and probiotic treatment efficacy across two human intervention trials
Prebiotic, probiotic, and combined (synbiotic) interventions often show variable outcomes across individuals, driven by complex interactions between introduced biotics, the endogenous microbiota, and the host diet. Predicting individual-specific success or failure of probiotic and prebiotic therapies remains a major challenge. Here, we leverage microbial community-scale metabolic models (MCMMs) to forecast probiotic engraftment and microbiota-mediated short-chain fatty acid (SCFA) production in response to probiotic and prebiotic interventions. Using data from two clinical trials, testing a five-strain probiotic combined with the prebiotic inulin designed to improve metabolic health and an eight-strain probiotic designed to treat recurrent Clostridioides difficile infections, respectively, we show that MCMM-predicted engraftment largely agrees with measurements, achieving 75-80% accuracy. Engraftment probabilities varied across taxa, with Akkermansia muciniphila and Bifidobacterium infantis showing higher predicted and observed engraftment than the clostridial strains. MCMMs captured treatment-driven shifts in predicted SCFA production, and higher model-predicted growth rates of A. muciniphila were negatively associated with glucose AUC in the synbiotic trial, providing clues about the mechanisms underlying treatment efficacy. Finally, extending these models to a longitudinal cohort undergoing a healthy diet and lifestyle intervention revealed substantial inter-individual variability in predicted responses to increasing dietary fiber, which were significantly associated with baseline-to-follow-up changes in cardiometabolic health markers. Finally, our simulation results suggested that personalized prebiotic selection may further enhance probiotic efficacy. Together, these findings demonstrate the potential of metabolic modeling to guide personalized microbiome-mediated interventions.
- Open Access
- 23 April 2024
- Published by Springer Nature in BMC Biology
- Vol. 22 (1) , 1-14
Meta-analysis of the human upper respiratory tract microbiome reveals robust taxonomic associations with health and disease
Background: The human upper respiratory tract (URT) microbiome, like the gut microbiome, varies across individuals and between health and disease states. However, study-to-study heterogeneity in reported case–control results has made the identification of consistent and generalizable URT-disease associations difficult. Results: In order to address this issue, we assembled 26 independent 16S rRNA gene amplicon sequencing data sets from case–control URT studies, with approximately 2–3 studies per respiratory condition and ten distinct conditions covering common chronic and acute respiratory diseases. We leveraged the healthy control data across studies to investigate URT associations with age, sex, and geographic location, in order to isolate these associations from health and disease states. Conclusions: We found several robust genus-level associations, across multiple independent studies, with either health or disease status. We identified disease associations specific to a particular respiratory condition and associations general to all conditions. Ultimately, we reveal robust associations between the URT microbiome, health, and disease, which hold across multiple studies and can help guide follow-up work on potential URT microbiome diagnostics and therapeutics.
- 23 April 2024
- Published by Springer Nature in BMC Biology
- Vol. 22 (1) , 1-14
Open AccessMeta-analysis of the human upper respiratory tract microbiome reveals robust taxonomic associations with health and disease
Background: The human upper respiratory tract (URT) microbiome, like the gut microbiome, varies across individuals and between health and disease states. However, study-to-study heterogeneity in reported case–control results has made the identification of consistent and generalizable URT-disease associations difficult. Results: In order to address this issue, we assembled 26 independent 16S rRNA gene amplicon sequencing data sets from case–control URT studies, with approximately 2–3 studies per respiratory condition and ten distinct conditions covering common chronic and acute respiratory diseases. We leveraged the healthy control data across studies to investigate URT associations with age, sex, and geographic location, in order to isolate these associations from health and disease states. Conclusions: We found several robust genus-level associations, across multiple independent studies, with either health or disease status. We identified disease associations specific to a particular respiratory condition and associations general to all conditions. Ultimately, we reveal robust associations between the URT microbiome, health, and disease, which hold across multiple studies and can help guide follow-up work on potential URT microbiome diagnostics and therapeutics.